Figure 1.

Use of AS, as a primary treatment strategy, for men in Sweden up to the age of 75 years diagnosed with very‐low‐risk prostate cancer in 2017 per county reported in the online interactive reporting system at http://www.npcr.se/RATTEN. At http://www.npcr.se/RATTEN the user can select: (1) source population; all or any of the six health care region(s); (2) level of comparison: hospital, county, or health care region; (3) unit of interest, here marked in red; (4) the year(s) of diagnosis; (5) age range of the source population; (6) risk category; (7) denotes the column with the number of men who received AS out of all men in this risk group. Data are not displayed for counties with fewer than five cases. Data from each private healthcare provider are shown only when one single healthcare region is used as the source population. Very‐low‐risk prostate cancer was defined as clinical stage T1c, Gleason Grade Group 1, PSA level of <10 ng/mL, PSA density <0.15 ng/mL, <8 mm total cancer length in ≤4 positive biopsy cores 6. Figure based on data on men diagnosed in 2017 reported up to 8 March 2018. In 2016, for which there is complete capture, exactly the same percentage of men up to the age of 75 years with very‐low‐risk cancer started AS (619/681; 91%).